World News – United States – Slack stock rises on potential Salesforce acquisition


. .

The news that Salesforce is interested in buying Slack, the popular chat company in the workplace, has propelled the smaller company’s stocks significantly higher today.

According to data from Yahoo Finance, Slack stocks are currently up nearly 25%. Slack is worth $ 36. 95 per share at the time of writing, valued at around $ 20. 8 billion. The famous former unicorn was worth only $ 15. 10 per share last year and worth up to $ 40. 07.

Conversely, Salesforce stock trades lower on the news, falling 3. 5% at the time of writing; Investors in the San Francisco-based SaaS pioneer were either unfazed by the combination idea or may have worried about the price it would take to bring the 2019 IPO to its knees.

Why Salesforce, a massive software company with a strong position in the CRM marketplace and eager to become an even bigger platform player, would want to buy Slack is not immediately clear, although there are potential benefits. This includes the ability to cross-sell the two companies’ products to each other’s customer base, potentially unleashing growth for both parties. For example, Slack has a broad market share within fast-growing startups, while Salesforce products are located in a variety of mega-corps.

TechCrunch reached out to Salesforce, Slack, and Slack’s CEO for comment on the opportunity of the deal. We’ll update this post with whatever we get.

While Salesforce bought Quip in 2016 for $ 750 million, which gave him some kind of document sharing and collaboration, Salesforce Chatter was the only social tool in the company’s arsenal. Buying Slack would give the CRM giant a solid base for corporate chatting, and likely a lot of synergy between customers and tools.

But Slack has always been more than just a chat client. Companies can use it to embed workflows. This fits well with the Salesforce family of products, which includes sales, service, marketing, and more. This enables companies to work both inside and outside the Salesforce ecosystem and create smooth and integrated workflows. While this is now theoretically possible, you can be sure that the integrations would be much closer if the two were combined.

Additionally, Holger Mueller, an analyst at Constellation Research, says this would provide Salesforce with a vital source of revenue that they are constantly looking for to keep their revenue engine running. « Slack could be a good candidate for strengthening its platform, but most of all it could be responsible for increasing the usage and stickiness of Salesforce products – as collaboration is important not only for CRM, but also for the growing work of vendors. com platform, « said Müller. He added it would be a way to tie it to former friend Microsoft.

That’s because Slack has come under fire from Microsoft in recent quarters when the Redmond-based software giant poured resources into its rival Teams service. The teams challenge Slack’s chat tools and Zoom’s video capabilities and have seen tremendous customer growth over the past few quarters.

If you find Slack headquartered among the bigger tech players, you can make sure Microsoft doesn’t drag it among the bulk of its corporate software sales. And Salesforce, sometimes an ally of Microsoft, wouldn’t mind adding the fast-growing slump to its own growing software revenue.

The question at this point depends on the price. Slack investors who don’t want to sell for less than a good premium on the pre-pop price per share are now feeling rather dated.

To put Biden’s tax plan into concrete terms, the Tax Policy Center (TPC) analyzed the many different things that were being said about how tax rules would change.

Electric car shares were sold on news of an investigation in China, while Nikola failed to convince investors of a proposed GM partnership.

Timothy Vogus, professor at Vanderbilt University’s Owen Graduate School of Management, reveals the « greatest thing people do wrong » when they walk into a showroom.

Now the bad news: – Aside from the expected social security (around Jan.. $ 300 / month if I wait until full retirement age, 1. $ 200 / month if I retire at 65) I have no pension or other sources of income. – I don’t have an impressive résumé that could lead to lucrative retirement jobs. Is there a way to last savings of 500. $ 000, especially given the miserably low interest rate environment?

Warren Buffett runs out of stocks. Berkshire Hathaway (Ticker: BRK. A, BRK. B) CEO Warren Buffett is possibly the most popular and successful investor in history, and Berkshires 13-F is the most anticipated filing on Wall Street each quarter. Here are eight stocks Warren Buffett bought.

(Bloomberg) – Bank of America Corp.. . The heads of state and government are planning bonuses at the end of the year, which break with the hopes of Wall Street traders for strong increases after a record run. Executives plan to keep the bonus pool for sales and trade at last year’s level despite a 20% jump in sales in the first nine months of this year, according to the people informed in the discussions on condition of anonymity. The process is still at an early stage and will go through rounds of negotiation and approval. The bank’s leadership is weighing the rewards against the stresses of a pandemic that has hurt the consumer business and increased costs. But the reluctance is already causing outrage among employees who expected to be well paid for a banner year. Executives still have time to campaign for higher payouts at top performing desks and could actually argue for more money, some of the people said. But even then, the increases are likely to be modest. A company spokesman declined to comment. Tensions within Bank of America provide a glimpse into talks expected to unfold on Wall Street in the coming weeks. There, big banks pay close attention to the compensation decisions of their competitors when determining their own payouts. Legions of traders had hoped to share the spoils of the 2020 wild markets that the pandemic and U. . S.. . Politics repeatedly triggered customer orders. However, industry leaders are grappling with bigger issues including credit losses, the possibility that the trade damage will not last, and the optics of handing out bundles of money to well-paid employees at a time of economic misery. Moderate Expectations Among Wall Street chief executives, Brian Moynihan of Bank of America is particularly familiar with changing political winds after he rebuilt the company’s troubled businesses and reputation after the 2008 crisis. In recent years he has publicly spoken out in favor of stricter environmental, social and governance standards. Now he steers the company under the elected President Joe Biden in the rise of a democratic government. The investment bank’s final bonus decisions will depend on how the fourth quarter develops. However, early conversations are already causing senior executives to soften expectations as they near year-end meetings with subordinates. In an unusual Sunday briefing, a manager in the pension department informed members of his group that they should prepare for bonuses, which are flat at best. So far the tone on Wall Street had been more optimistic, with some compensation advisors predicting generous increases. Earlier this month, a closely watched survey by Johnson Associates Inc. . Estimated stock traders could see their bonuses increase by about 25%, while bond traders would see their bonuses increase by 45% or more. Rivals Watching The deliberations at Bank of America, one of the largest employers in the industry, will make it easier for rivals to outperform such dramatic increases, even if they grant increases. While Bank of America’s stock trading operations hit a record in the first quarter, there were bumps this year too. In a second quarter filing, the bank noted « poor trading performance » in the unit’s derivatives business, with people familiar with the matter claiming to have lost more than $ 100 million on some positions outside the United States. S.. . The division has also seen staff reorganizations that culminated in October’s announcement that long-time stock chief Fab Gallo would step down and leave. The bank’s bond trading revenue grew nearly 22% in the first nine months of the year. Former co-head of that business, Jim DeMare, was promoted to head of global sales and trading in July. For more articles like this, please visit us on Bloomberg. comSubscribe now to stay one step ahead with the most trusted business news source. © 2020 Bloomberg L. . P. .

In May 2019, two veteran money managers shared their philosophy with MarketWatch readers that when choosing stocks for income, investors shouldn’t focus too much on the highest dividend yields. The original article included comments from Mike Loewengart, who is now Managing Director, Investment Strategy at E-Trade (which was acquired by Morgan Stanley in October), and Lewis Altfest, President of Altfest Personal Wealth Management, which manages approximately $ 1. 4 billion for private customers in New York. Loewengart believes that a good approach for income-seeking investors is to focus on total return rather than dividend yield.

The Dow Jones Industrial Average fell from record highs when Tesla shares briefly skidded on a vehicle recall. Nio showed up during an investigation by the Chinese government.

What would Treasury Secretary Janet Yellen mean for incentives, Fed policy, banking regulation and Bitcoin?

A Canadian police officer overseeing the arrest of Huawei chief financial officer Meng Wanzhou forwarded to an arrest officer a « strong proposal » from her manager to arrest Meng on the plane she was arriving on, the court said Tuesday. Huawei lawyers have alleged that U. during Meng’s arrest at Vancouver Airport two years ago. S.. . and the Canadian authorities coordinated the use of CBSA’s additional investigative powers to interrogate her without a lawyer present before Canadian police arrested Meng on a U warrant. S.. . Bank fraud charges.

Which stocks are either a fan favorite or a must-have? Penny stocks. For less than $ 5 apiece, these tickers are particularly controversial on Wall Street as both proponents and naysayers make strong arguments. These names are too attractive for the risk-tolerant investor to ignore. Get more for your money with their low prices. In addition, even a slight appreciation of the share price can lead to massive percentage gains and thus to substantial returns for investors. However, there is one but here. The critics point out that there could be a reason for the low price, whether it be poor fundamentals or overwhelming headwinds. So how are investors supposed to determine which penny stocks are ready to make it big? Tracking the activity of the investing titans is one strategy. Enter billionaire Steven Cohen. The legendary stock picker who started his career as an investor at Gruntal & Co. Started. There he managed equity for 14 years and founded S. . ONE. C Capital Advisor in 1992. In 2014, his investment business was switched to Point72 Asset Management, one over 1. 500 people registered investment advisory firm. Throughout his career, Cohen has consistently generated tremendous returns for clients and has made Point72 Chairman, CEO and President a Guru on the Road. When we reached out to Cohen for inspiration, we took a closer look at three penny stocks. Cohen’s Point72 recently took steps. Using TipRanks’ database to find out what the analyst community had to say, we learned that every ticker has buy ratings and huge upside potential. Cocrystal Pharma (COCP) To bring targeted solutions to market, Cocrystal Pharma develops antiviral therapeutics to treat severe or chronic viral diseases such as influenza, hepatitis C, gastroenteritis caused by norovirus and COVID-19. Based on the progress of his pipeline and $ 0. Some see a clear profit in the future of COCP. Cohen is among those who have high hopes for this name in healthcare. Point72 hit COCP for the first time and bought more than 2. 8 million shares. The value of the company’s new stake is over $ 2. 5 million. Meanwhile, the 5-star analyst Raghuram Selvaraju from H. . C.. . Wainwright urges customers to focus on COCP’s achievements over the past few months. In August, preclinical animal studies of coronavirus antiviral compounds that were potential development candidates for the company were published in the medical journal Science Translational Medicine. It should be noted that under license agreements with the Kansas State University Research Foundation (KSURF), COCP has an exclusive, royalty-paying right and license to certain human antiviral compounds and small molecule inhibitors against coronavirus, picornavirus, and calicivirus that are under patent rights controlled by KSURF. Selvaraju said the company plans to further develop these compounds to treat coronavirus-related infections. In addition, last month Cocrystal released promising in vitro and 7-day toxicity data for its preclinical influenza A lead molecule, CC-42344, which is being investigated in (IND) -enabled studies as a potential treatment for seasonal and pandemic influenza strain A.. . Management expects the IND-eligible studies to be completed and the candidate to participate in clinical trials in 2021. Upon closer inspection of CC-42344, Selvaraju points out that it is an « effective broad spectrum inhibitor of the influenza replication enzyme against the PB2 subunit » and that it has strong synergistic effects in combination with approved antiviral influenza drugs such as Tamiflu (oseltamivir) and Xofluza ( Baloxavir). « He argues that, as recent data show that the drug maintains single-digit nanomolar potency against baloxavir-resistant influenza A strain, it » could « facilitate demonstrating the superiority of CC-42344 in filing for FDA approval. To this end, Selvaraju rates COCP at a purchase and $ 4. 50 course target. Should this goal be achieved, there could be upside potential of 417% in stock. (To see Selvaraju’s track record, click here. ) A total of 2 purchases and no holds or sells were awarded in the last three months. Hence, the analyst consensus is a moderate buy. At $ 4. 75, the average target price is 452%. . (See COCP stock analysis on TipRanks) DiaMedica Therapeutics (DMAC) Using its patented and licensed technologies, DiaMedica Therapeutics develops novel recombinant proteins for the treatment of kidney and neurological diseases. Currently go for $ 4. 3 pieces, this name has received high praise lately. Point72 also reflected a new position for Cohen’s company, buying 800 in the third quarter. 000 shares valued at $ 3. 4 million. 5-star analyst Etzer Darout, who writes for Guggenheim, points out that the company’s lead drug, DM199, a synthetic kallikrein-1 (KLK1) replacement therapy for patients with chronic kidney disease (CKD) and acute ischemic stroke ( AIS), a key is part of his bullish thesis. According to the analyst, early clinical data on DM199 is in U. . S.. . Patients and KLK1 derived from pigs and human urine in Asia serve as “clinical evidence of the role of KLK1 therapy and the potential of DM199 as a potentially differentiated therapy for CKD and stroke. In the future, the analyst assumes that the next clinical milestone for therapy will be proof-of-concept data in three CKD populations: patients with immunoglobulin A nephropathy (IgAN), hypertensive African-Americans with APOL1 gene mutations (APOL1 HT AAs) and patients with diabetic kidney disease (DKD). In Darout’s view, however, the main value driver is IgAN. “Competitive programs advancing IgAN have shown improvements in proteinuria with stable eGFR, two key markers of kidney function. However, early clinical experience suggests that DM199 has the potential to improve both eGFR and proteinuria, which would be a significant benefit to our assumptions. If DM199 can demonstrate a decrease in proteinuria of more than 25% and an increase in eGFR (which is achievable according to initial data), this would increase our confidence that DM199 will become the standard of care beyond all of the CKD indications we are currently modeling could, ”explains Darout. Looking at the market opportunity, there are around 690 in the US. 000 strokes. S.. . per year (1. 1 million strokes in EU), 87% of which are considered ischemic strokes, says American Heart Association (AHA). Additionally in the U. . S.. . 90% of patients with acute ischemic stroke receive palliative care. According to Darout’s estimates, AIS could represent a $ 3 billion to $ 5 billion chance for DMAC in the US if half of palliative care patients are treated with DM199. S.. . So it should come as no surprise that Darout stayed with the cops. In addition to a buy recommendation, he left a target price of $ 16 on the stock. Investors could pocket a 277% gain if that goal is met over the next twelve months. (To see Darout’s track record, click here. ) What are other analysts saying? 2 Buys and no holds or sells lead to a consensus among analysts on moderate buys. Given the average price target of $ 15, stocks could rise 253% over the next year. (See DMAC stock analysis on TipRanks. ) To find great ideas for trading penny stocks at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that brings together all the insights into TipRanks stocks. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.

President-elect Joe Biden wants to help Americans save for their golden years by expanding access to retirement plans, strengthening social security, and making health care more affordable.

Jumia Technologies (NYSE: JMIA) is an African e-commerce company with a population of 600 million people. A presentation in November outlined the company’s turnaround efforts and plans for future growth, which are summarized below. Jumia E-Commerce: Jumia has 6. 7 million active customers per year and over 28 million orders via the platform last year. Jumia’s third party vendors cover 90% of the platform items, with 110. 000 active sellers are part of the Jumia ecosystem. 78 percent of African online shoppers have bought from Jumia in the past 12 months, and 88 percent of those have made additional purchases over the same period. Related link: Citron Declares Change of Heart at Jumia Technologies, 0 Price Target JumiaPay: One of Jumia’s key assets could be the JumiaPay fintech platform, as approximately 34% of the company’s transactions are processed through JumiaPay. A slide in the Jumia presentation compares Jumia to other winning stocks that have shown that e-commerce is a big driver of online payments adoption. The companies named on the slide are eBay (NASDAQ: EBAY) with Paypal (NASDAQ: PYPL), MercadoLibre (NASDAQ: MELI) with Mercado Pago, Alibaba Group (NYSE: BABA) with AliPay and WeChat with WeChat Pay from Tencent Holdings (Pink : TCEHY). JumiaPay revenue increased 74% year over year in the first nine months of 2020. Jumia Logistics: Jumia has its own logistics business that supports its e-commerce platform. Jumia said its logistics business is the technology and data-driven answer to Africa’s logistical challenges. The business is seen as a major barrier to competition for other companies in the region. The logistics business comprises 20 million packages, 50% of which are delivered to primary cities, 25% to secondary cities and 25% to rural locations. Business relocation could pay off: Over the past year, Jumia has reorganized its operations to focus on profitability. Jumia left three poorly performing countries and left its travel business. Gross profit margins increased 514 basis points year over year for the third quarter. Jumia reported its first breakeven quarter ahead of G&A in the third quarter. Adjusted EBITDA also improves in each quarter of fiscal 2020 compared to fiscal 2019, where losses grew larger in each quarter. Growth Opportunities: Jumia identified future growth and said the long-term goal was to « maximize the value of each asset » and break JumiaPay and Jumia Logistics into separate companies. The plan also sees Jumia expanding into Ethiopia, DR Congo and Angola with populations of 105 million, 81 million and 30 million, respectively. Price Action: Jumia’s shares are down 4% to $ 29. 06 on Tuesday after a new 52-week high of $ 33. 42. Shares are up 348% since the start of the year. Disclosure: The author has a long position in JMIA. More information from Benzinga * Click here to go to Benzinga’s option deals. * Ozone IPO: What Investors Should Know About Russia’s Amazon * Jumia Falls 20% On Third Quarter Earnings, Progressing Towards Profitability (C) 2020 Benzinga. com. Benzinga does not offer investment advice. All rights reserved.

Dow Jones futures were in the spotlight early Wednesday after the Dow Jones Industrial Average first hit 30. Had exceeded 000.

Investors are concerned that big oil companies like ExxonMobil aren’t making enough to fund their dividends in a sustainable way.

Marko Kolanovic of JPMorgan sees many reasons for optimism in a report on current market conditions and future strategic perspectives. Kolanovic sees that risk has diminished over the past few weeks and given the usual daily fluctuations, markets should see continued recovery. According to Kolanovic, the biggest news is the positive reports about the rapid development and imminent availability of a COVID-19 vaccine. This is a ‘game changer’ that will allow investors to ‘see the recent surge in COVID-19 cases leading up to the impending end of the pandemic and wider reopening of the economy. “In terms of market importance, the split result of the national elections comes in second. Kolanovic describes a Biden presidency combined with increased Republican strength in the House of Representatives and a sustained majority in the Republican Senate as « the best of both worlds ». A divided government is unlikely to undo the pro-business measures put in place by the Trump administration, while Biden is likely to ease the trade war. According to the Kolanovic team, the result will be “less market volatility, which could lead to inflows into risk assets. To that end, JPM’s stock analysts scanned the tickers looking for those likely to win or lose in the months ahead. Of particular interest, we pulled in TipRanks data for two stocks the company is forecasting double-digit growth and one JPM says it will avoid. Vroom, Inc. . (VRM) We’re starting with Vroom, an online used car dealer. In addition to automobiles, the company also sells parts and accessories, and offers insurance, rental cars, and purchases only to US customers. Vroom is a newcomer to the markets. The IPO took place in June and rose rapidly, reaching on Jan.. September culminated. Since then, stocks have slid, down 22% since day one. The rise and fall is the result of conflicting tailwinds and headwinds pushing against the stock. On the upside, Vroom picked up during the general move to online retail. The company’s focus on used vehicles was also beneficial during the pandemic when customers were nervous or financially troubled – but in both cases they were reluctant to spend large sums on a new car. On the negative side of the ledger, this spending restraint spilled over into the used car market. Vroom struggled with low margins while lowering prices to attract sales. Analyst Rajat Gupta, who covers the stock for JPM, sees the current level of the stock as an opportunity for investors. The bad times are likely only temporary, he believes, and this company will take off. « Net-Net, as short-term expectations are now being reset and unit growth and gross profit can be accelerated through 2021, we see the line-up as favorable to the stock in the short to medium term with few incremental negative catalysts. We believe that execution will be critical given the heavy reliance on third parties for key operational issues such as overhaul and logistics, ”Gupta wrote. In line with this assessment, Gupta rates the share as overweight (i. e. Buy), and its target price of $ 70 implies an upward movement of 91% for the coming year. (To see Gupta’s track record, click here. ) Even after the stock’s fall, Vroom retains a strong buy out of analyst consensus. Scoring is based on 11 reviews including 10 purchases and 1 sale. VRM sells for $ 36. 81 and its $ 59. The average target price of 40 indicates that growth of ~ 61% is possible over the one-year horizon. (See VRM stock analysis on TipRanks) Colfax Corporation (CFX) Next up is Colfax, a niche manufacturer. Colfax manufactures a range of equipment for the welding, medical device, and air and gas handling markets, from medical equipment for joint reconstruction to welding helmets and cutting torches. While it sounds incongruous, the combination works for Colfax and the company is seeing a turnaround in the second quarter of 20 due to corona crisis losses. The result for the third quarter of 41 cents per share was both good and bad. It was down 32% year over year, but more than quadrupled sequentially, beating estimates. Revenue increased sequentially by 29% to 805 million. USD. Management expects further sequential improvements for the remainder of 2020 and forecasts annual earnings in the range of 45 to 50 cents per share. 5-star analyst Stephen Tusa, who represented JPM, stated, “[We] see the stock as relatively cheap compared to close competitors in the fab tech and med tech space, with a clear upward trend after COVID-19, which is apparently not fully realized. The assessment has so far been compared with the expectations of the comparative year. CFX has strong brands and franchises … and an underrated productivity opportunity as the primary end market at Fab Tech recovers and demand at Med Tech increases. Tusa supports his optimistic comments with an overweight (i. e. Buy) rating and a price target of USD 52 show his confidence in an upward trend of 38% for a year. (To see Tusa’s track record, click here. ) Overall, Colfax has a moderate buy rating from analyst consensus based on 8 ratings split into 5 buys, 2 holds and 1 sell. The majority, however, assume that the shares will remain in a range of currently USD 38 for the time being. 63 shows average target price. (See CFX stock analysis on TipRanks) Beyond Meat (BYND) Last on today’s list of JPM calls is Beyond Meat, a company that made waves last year when it raised over $ 3. 8 billion when it went public. The company offers a vegetarian meat substitute and markets it as more nutritious, better tasting – and more like meat – than competing products. The company was founded in 2009 and has expanded its product range to include simulated beef, pork and chicken products. Overall, the BYND share continues to have a positive facade. Stocks are up 88% since the start of the year, and the company posted net income in the first quarter of 20 when the corona crisis began. Since then, however, earnings have turned negative – and worse, revenue saw a sharp sequential decline in the third quarter. The latest quarterly numbers showed that it was at the top of $ 94 million, 16% less than the second quarter and well below the forecast of $ 133 million, and an EPS loss of 28 cents – far worse than forecast 3 -Cent loss. Beyond Meat’s biggest success came from declines in the restaurant business, which were only partially offset by a 40% increase in grocery sales. The company announced a partnership with McDonald’s to provide the meat substitute for the fast-food giant’s new McPlant menu, but even that announcement was botched. BYND shares fell sharply when it was rumored that McD’s developed the meat substitute in-house. While that misunderstanding has been corrected, BYND has only partially come back. In short, this company is facing serious headwinds in the short term and JPM advises caution as “visibility is so low and the last quarter is surprisingly weak. Ken Goldman, who was rated 5 stars by TipRanks, writes of BYND: “We are now trying to model a company for which (a) we don’t know exactly why 3Q was so bad (the company’s statement didn’t seem confirmed be) by meaningful data) and (b) the partnership with McDonald’s could either be a game changer or a dud. « Goldman’s caution is evident from his underweight position (i. e. a Sell), and its target price of $ 104 suggests a 26% downtrend for the stock. (To see Goldman’s track record, click here. ) JPM isn’t the only company advising caution here. Beyond Meat’s analyst consensus rating is a moderate sell based on 2 buys, 7 holds, and 7 sells set in the past few weeks. The stock sells for $ 141. 91 and its average target price of $ 110. 71 indicates a likely downward trend of 22% in the coming year. (See BYND stock analysis on TipRanks. ) To find great ideas for trading stocks at attractive valuations, visit TipRanks ‘Best Stocks to Buy, a newly launched tool that brings together all of TipRanks’ stock insights. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.

Exxon’s internal projections for oil prices have turned bearish lately as the energy giant cut jobs and investments to protect its dividend.

Moderna surfaced Wednesday after the company signed a deal with the European Commission for at least 80 million doses of its coronavirus vaccine. The drug is based on messenger RNA technology.

Nikola shares (NKLA) traded 15% lower on the Wednesday before going public and abandoned 17% rise on Tuesday.

Nikola Corp. stock. . fell 16. 1% in premarket trading on Wednesday, which puts them on track for a record eight-day winning streak in which the electric vehicle maker’s stock shot up 76. 3%. In an interview late Tuesday on CNBC’s « Mad Money with Jim Cramer, » CEO Mark Russell assured investors of this partnership with General Motors Corp.. Not. Announced in September that GM would get a $ 2 billion stake in Nikola, it would continue to go through it, CNBC reported. Also in the interview, Russell said he couldn’t comment on what founder Trevor Milton, who left the company in September, would do at 92. 2 million shares of Nikola common stock he owned when the lock expires on December. 1, although many other insiders have agreed to end their lock-up agreements by Jan.. April 2021. A total of 161 million shares, or around 42% of the ordinary shares issued, will be admitted for sale from December. 1 expire as lock-up agreements. Nikola shares sale on Wednesday as shares of other electric vehicle manufacturers join Tesla Inc.. Withdraw before the open. down 1. 5%, Nio Inc. . shed 8. 8% and Workhorse Group Inc. . slide 9. 4%. Meanwhile, the futures for the Nasdaq 100 are up 0. 1% ahead of the Open and S&P 500 futures are down 0. 1%.

Salesforce, Slack Technologies, Stock, NYSE: CRM, Cloud Computing, Customer Relationship Management

World News – USA – Slacks shares rise due to a possible Salesforce acquisition



Donnez votre point de vue et aboonez-vous!


Votre point de vue compte, donnez votre avis

[maxbutton id= »1″]